+1.212.901.8009 sclassen@alzdiscovery.org

12th ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE
An Educational Course on Translating Research into Drugs
Presented by the Alzheimer’s Drug Discovery Foundation
February 4-6, 2018 • Washington, DC

Preliminary Program

All sessions will be held at the The Ritz-Carlton, Pentagon City located at 1250 South Hayes Street, Arlington, Virginia 22202.

SUNDAY, FEBRUARY 4, 2018
2:00pm - 5:00Registration
4:00 - 4:20Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
4:20 - 5:00KEYNOTE: Executing a Drug Discovery Program with an Eventual Clinical Trial in Mind
Richard Mohs, PhD—Global Alzheimer’s Platform
5:00 - 5:10Q&A
5:10 - 7:00Welcoming Reception
MONDAY, FEBRUARY 5, 2018
7:30am - 8:30Breakfast
8:30 - 8:40Opening Remarks and ADDF Funding Opportunities
Andrew Koemeter-Cox—Alzheimer's Drug Discovery Foundation
8:40 - 8:50NIA Opportunities for Translational Research Funding
Lorenzo Refolo, PhD—National Institute on Aging
8:50 - 9:00NINDS Opportunities for Translational Research Funding
Amir Tamiz, PhD—National Institute of Neurological Disorders and Stroke
Session I. Embarking on a Drug Discovery Campaign
Chair: Marcie Glicksman, PhD—Orig3n, Inc.
9:00 - 9:05Session Overview:
Marcie Glicksman, PhD—Orig3n, Inc.
9:05 - 9:25What Makes a Good Translational Target?
Samuel Hasson, PhD—Pfizer, Neuroscience Unit
9:25 - 9:35Q&A
9:35 - 9:55New Trends and Technology in Assay Development
Marcie Glicksman, PhD—Orig3n, Inc.
9:55 - 10:05Q&A
10:05 - 10:25Phenotypic Screening in Drug Discovery: An Industry Perspective
Claire Steppan, PhD—Pfizer
10:25 - 10:35Q&A
10:35 - 11:00EXHIBITOR SESSION AND BREAK
Session II. Starting at the End: The Pharmacology—Chemistry Interface in Preclinical Drug Development
Chair: D. Martin Watterson, PhD—Northwestern University
11:00 - 11:05Session Overview:
D. Martin Watterson, PhD—Northwestern University
11:05 - 11:25Chemogenomic Library Screening in Drug Discovery
Lyn Jones, PhD—Jnana Therapeutics
11:25 - 11:35Q&A
11:35 - 11:55CNS Medicinal Chemistry Basics
Amy Ripka, PhD—Lucy Therapeutics
11:55am - 12:05pmQ&A
12:05 - 12:25Pharmacology Driven Optimization in Candidate Development
D. Martin Watterson, PhD—Northwestern University
12:25 - 12:35Q&A
12:35 - 12:45Young Investigator Scholarship Awards Presented
Nicholas McKeehan—Alzheimer’s Drug Discovery Foundation
12:45–1:15YOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #1-15
1:15 - 2:15LUNCH
Session III. Drug Discovery: From Lead to Clinical Candidate
Chair: Edward Spack, PhD— Vector BioSolutions
2:15 - 2:20Session Overview:
Edward Spack, PhD— Vector BioSolutions
2:20 - 2:40PK/PD in Preclinical Development
Sharon Rosenzweig-Lipson, PhD—AgeneBio, Inc.
2:40 - 2:50Q&A
2:50 - 3:10Drug Delivery for CNS Disease
William Banks, MD—University of Washington
3:10 - 3:20Q&A
3:20 - 3:40Improving the Translatability of Animal Models of Neurodegeneration
Caroline Zeiss, PhD—Yale University
3:40 - 3:50Q&A
3:50 - 4:10Requirements for an IND
Edward Spack, PhD— Vector BioSolutions
4:10 - 4:20Q&A
4:20 - 4:40ADDF Access
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
4:50 - 5:50Partnering/Mentoring Session (pre-registration required)
4:40 - 6:40Networking Reception
TUESDAY, FEBRUARY 6, 2018
7:30am - 8:00Partnering/Mentoring Session (pre-registration required)
7:30 - 8:20Continental Breakfast
8:20 - 8:25Welcome & Opening Remarks
Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
8:25 - 9:05KEYNOTE:
Role of Academic Drug Discovery in the Quest for New CNS Therapeutics

Barbara Slusher, PhD—Johns Hopkins Drug Discovery Center
9:05 - 9:15Q&A
Session IV. Strategies for Challenging CNS Targets—Case Study Examples
Chair: Kurt Brunden, PhD—University of Pennsylvania
9:15 - 9:20Session Overview:
Kurt Brunden, PhD—University of Pennsylvania
9:20 - 9:40Academic-Industry Partnership
Kurt Brunden, PhD—University of Pennsylvania
9:40 - 9:50Q&A
9:50 - 10:10RNA-Directed Therapeutics for FTD and ALS
Len Petrucelli, PhD—Mayo Clinic
10:10 - 10:20Q&A
10:20 - 10:50EXHIBITOR SESSION AND BREAK
10:50 - 11:10Clinical Development of a Selective PDE4D Inhibitor
Mark Gurney, PhD—Tetra Discovery Partners
11:10 - 11:20Q&A
11:20 - 11:40Neurophysiological Biomarkers for Neurodegenerative Disease Drug Development
Daniel Javitt, PhD—Columbia University Medical Center
11:40 - 11:50Q&A
11:50 - 12:20pmYOUNG INVESTIGATOR SCHOLARSHIP POSTER SESSION
Poster Abstracts #16-30
12:20pm - 1:20LUNCH
Session V. Commercialization Strategies: Developing Science into Products
Chair: Frank Longo, MD, PhD—Stanford University and PharmatrophiX
1:20 - 1:25Session Overview:
Frank Longo, MD, PhD—Stanford University & PharmatrophiX
1:25 - 1:45Intellectual Property Strategies: What and When to File for Patent Protection
Leslie Meyer-Leon, PhD, JD—IP Legal Strategies Group PC
1:45 - 1:55Q&A
1:55 - 2:15Lessons Learned in Drug Development from an Academic and Small Biotech Perspective
Frank Longo, MD, PhD—Stanford University & PharmatrophiX
2:15 - 2:25Q&A
2:25 - 2:45Finding and Working with Investors/Industrial Partners
Joel Braunstein, MD, MBA—C2N Diagnostics
2:45 - 2:55Q&A
2:55 - 3:00pmClosing Remarks:
Howard Fillit, MD—Alzheimer's Drug Discovery Foundation